These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19383971)

  • 1. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
    Ellis L; Bots M; Lindemann RK; Bolden JE; Newbold A; Cluse LA; Scott CL; Strasser A; Atadja P; Lowe SW; Johnstone RW
    Blood; 2009 Jul; 114(2):380-93. PubMed ID: 19383971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
    Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
    Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
    Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
    Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
    Edwards A; Li J; Atadja P; Bhalla K; Haura EB
    Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
    Haefner M; Bluethner T; Niederhagen M; Moebius C; Wittekind C; Mossner J; Caca K; Wiedmann M
    World J Gastroenterol; 2008 Jun; 14(23):3681-92. PubMed ID: 18595135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
    Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
    Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
    Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
    Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
    Newbold A; Lindemann RK; Cluse LA; Whitecross KF; Dear AE; Johnstone RW
    Mol Cancer Ther; 2008 May; 7(5):1066-79. PubMed ID: 18483296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.
    Gandesiri M; Chakilam S; Ivanovska J; Benderska N; Ocker M; Di Fazio P; Feoktistova M; Gali-Muhtasib H; Rave-Fränk M; Prante O; Christiansen H; Leverkus M; Hartmann A; Schneider-Stock R
    Apoptosis; 2012 Dec; 17(12):1300-15. PubMed ID: 23011180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
    PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
    Bluethner T; Niederhagen M; Caca K; Serr F; Witzigmann H; Moebius C; Mossner J; Wiedmann M
    World J Gastroenterol; 2007 Sep; 13(35):4761-70. PubMed ID: 17729398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
    Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
    Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway.
    Hasegawa H; Yamada Y; Tsukasaki K; Mori N; Tsuruda K; Sasaki D; Usui T; Osaka A; Atogami S; Ishikawa C; Machijima Y; Sawada S; Hayashi T; Miyazaki Y; Kamihira S
    Leukemia; 2011 Apr; 25(4):575-87. PubMed ID: 21242994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
    Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
    Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
    Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
    PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.